Pdcd4 is a novel transformation suppressor that is highly expressed in promotion-resistant (P7) mouse epidermal JB6 cells but not in susceptible (P+) cells. Overexpression of pdcd4 cDNA in stably transfected P+ cells rendered cells resistant to tumor promoter-induced transformation, indicating that elevated expression of Pdcd4 protein is sucient to suppress neoplastic transformation. To determine whether Pdcd4 suppresses neoplastic transformation through inhibiting known transformation required events, we examined the possibility that pdcd4 inhibited the activation of AP-1 or NF-kB dependent transcription or of ornithine decarboxylase (ODC) activity. Activation of AP-1-dependent transcriptional activity was inhibited by pdcd4 expression in a concentration dependent manner. In contrast, Pdcd4 slightly increased NF-kB-dependent transcription and did not alter ODC enzymatic activity. Previous studies suggested that activation of AP-1 was required for P+ cell transformation as well as for tumor promotion in vivo. These results indicate that Pdcd4 functions as a transformation suppressor, possibly through inhibiting AP-1 activation in combination with other factors such as enhancing NF-kB activation. Pdcd4 may thus constitute a useful molecular target for cancer prevention. Oncogene (2001) 20, 669 ± 676.
Introduction
The JB6 mouse epidermal clonal genetic variant cell system is a unique cell culture model for studying tumor promoter-dependent biochemical events occurring during preneoplastic progression (Cmarik and Colburn, 1997; Colburn et al., 1979 Colburn et al., , 1981 . Promotion-susceptible (P+) JB6 cells undergo neoplastic transformation in response to tumor promoters such as the phorbolester 12-O-tetradecanoylphorbol-13-acetate (TPA) and tumor necrosis factor-a (TNF-a), forming anchorage-independent colonies in soft agar (Colburn et al., 1979) and tumors when injected into mice (Takahashi et al., 1986; Colburn, 1980) . Promotion-resistant (P7) variants are resistant to promoterinduced anchorage-independent neoplastic transformation. Using dierential display of mRNA, we identi®ed a gene, pdcd4, which was preferentially expressed in P-cells (Cmarik et al., 1999) . The murine pdcd4 gene cDNA is identical to murine MA-3 (Shibahara et al., 1995) and TIS (Onishi and Kizaki, 1996) genes, and highly homologous to human H731 and 197/15 (Azzoni et al., 1998) genes. Expression of the MA-3 gene was upregulated with apoptosis in response to several inducers (Shibahara et al., 1995) . The TIS gene was down-regulated by treatment with topoisomerase inhibitors in mouse lymphoma cells (Onishi and Kizaki, 1996) . No causal relationship to apoptosis or to topoisomerase inhibitor-induced cytotoxicity has been established. Expression of anti-sense pdcd4 in Pcells lowered Pdcd4 protein levels while producing a gain of transformation response (Cmarik et al., 1999) . This result constituted the ®rst evidence for a biological function of Pdcd4, namely to inhibit neoplastic transformation. Thus, although reduction in Pdcd4 protein levels is required for transformation, it is not known whether expression of pdcd4 alone is sucient to inhibit neoplastic transformation.
A number of signal transduction events have been implicated as required events in tumor promotion using the mouse JB6 model (Huang et al., 1996 (Huang et al., , 1997 (Huang et al., , 1999 Amstad et al., 1994 Amstad et al., , 1997 Chang and Chambers, 2000; Hsu et al., 2000) . Transactivation of transcription factors AP-1 and NF-kB is required for TPA-or TNFa-induced neoplastic transformation (Dong et al., 1994; Li et al., 1997; Watts et al., 1998; Hsu et al., submitted) . The requirement for elevated AP-1 and NF-kB was shown to extend to human keratinocyte progression and for AP-1 to in vivo mouse skin tumor promotion (Young et al., 1999) models. Inhibition of AP-1 and/or NF-kB transcriptional activity by gene or small molecule inhibitors resulted in inhibition of TPA-or TNFa-induced neoplastic transformation. Transcription factors AP-1 and NF-kB regulate several genes whose expression may play a role in cell dierentiation or transformation (Angel and Karin, 1991; Foo and Nolan, 1999) . Treatment with tumor promoters such as TPA activates AP-1 dependent transcription by increasing the binding of AP-1 complexes to the AP-1 sequences in target gene promoters and by stimulating posttranslational activation of AP-1 proteins. NF-kB exists in an inactive form when it is associated with the inhibitory IkB protein (Baldwin, 1996) . Upon induction, IkB is phosphorylated and released from the NF-kB complex. NF-kB then activates appropriate target genes.
Activation of ornithine decarboxylase (ODC) activity is another required event for neoplastic transformation (Jansen et al., 1999) . ODC catalyzes the decarboxylation of ornithine to putrescine and is the key enzyme in the mammalian polyamine biosynthesis pathway (Heby and Persson, 1990) . Polyamine metabolism plays a crucial role in cell dierentiation, proliferation, and malignant transformation (Pegg, 1986) . TPA-induced ODC activity has been shown to be essential for neoplastic transformation in JB6 cells (Jansen et al., 1999) and in mouse skin (O'Brien et al., 1997) . Inhibition of ODC activity by a-di¯uoromethylor-nithine blocked TPA-induced neoplastic transformation in P+ cells and induction of mouse skin papillomas by TPA. Recently, Jansen et al. (1999) showed that TPAinduction of ODC gene expression and activity occurred independently of AP-1 transactivation.
In the present study, we demonstrate that overexpression of Pdcd4 protein is sucient to inhibit TPA-induced transformation in JB6 P+ cells. To explore the possible mechanism by which Pdcd4 protein inhibits neoplastic transformation, we examined the eect of Pdcd4 expression on transformation required events. Pdcd4 inhibits AP-1 activation in a concentration dependent manner while slightly enhancing NF-kB activation and producing no eect on ODC activation. Pdcd4 protein may owe its neoplastic transformation inhibiting activity to inhibition of AP-1 dependent transactivation.
Results

Pdcd4 protein is 64 kDa in size
Previously, we demonstrated that pdcd4 mRNA and protein were preferentially expressed in P7 cells (Cmarik et al., 1999) . However, the immunoblot used human H731 (highly homologous to Pdcd4) antibody showed multiple bands having molecular masses of 51 ± 64 kDa. These multiple bands may arise from non-speci®c interaction since the polyclonal human H731 antibody was raised against partially puri®ed bacterial recombinant H731 protein . In order to more accurately estimate both the molecular size and the relative amount of the Pdcd4 protein, we generated Pdcd4 antibody having high speci®city. A 15-amino acid peptide corresponding to residues 455 ± 469 of Pdcd4 protein was synthesized and used to generate Pdcd4-speci®c antibodies. As shown in Figure 1 , a single band of 64 kDa in size was detected using the newly generated pdcd4 antibody. This 64 kDa band was competed by 100 mg of peptide corresponding to residues 455 ± 469 of Pdcd4 protein (data not shown), thus con®rming the speci®city of this antibody. The expression level of this 64 kDa band, corresponding to Pdcd4, was 8 ± 10-fold higher in the P7 cells than in the P+ cells (Figure 1 ).
Expression of pdcd4 inhibits anchorage-independent transformation in P+ cells
Previously, we demonstrated that decreasing the endogenous level of Pdcd4 protein in P7 cells by overexpressing of antisense pdcd4 was accompanied by acquisition of transformation-sensitive phenotype (Cmarik et al., 1999) . This suggests that Pdcd4 expression must be down-regulated for transformation to occur. However, it is unknown whether expression of Pdcd4 alone is sucient to suppress tumor promoter-induced transformation in P+ cells. To test this hypothesis, pdcd4 cDNA was inserted into expression vector pcDNA3.1+, transfected into P+ cells, and selected by G418. The expression of the Pdcd4 protein was con®rmed by immunoblot using Pdcd4 antibody (Figure 2a) . The pooled-clone P+ transfectants (41/pdcd4-1, 41/pdcd4-3 and 41/pdcd4-4) express levels of Pdcd4 protein that are similar to each other and levels less than that in P7 (30.7b) cells but substantially greater than that in the control P+ (41/ vector) cells. The Pdcd4 protein level in pdcd4 pooledclone P+ (41/pdcd4) cells was 4 ± 6-fold higher than that in control P+ (41/vector) cells ( Figure 2a ). As shown in Figure 2b Pdcd4 protein inhibits AP-1 but slightly stimulates NF-kB activation Induction of tumor phenotype by TPA or TNFa in P+ cells occurred concomitantly with increased AP-1 and NF-kB activation (Bernstein and Colburn, 1989; De Benedetti, 1990; Li et al., 1997) . Inhibition of AP-1 and/ or NF-kB activation resulted in supression of neoplastic transformation (Dong et al., 1994; Li et al., 1997; Hsu et al., submitted) . Therefore, activation of both AP-1 and NF-kB appear to play key roles during neoplastic transformation. To test whether Pdcd4 protein blocks transformation by inhibiting activation of AP-1, NFkB, or both, a pdcd4 expression plasmid (pcDNApdcd4) was co-transfected with 46AP-1 luciferase reporter plasmid (46AP-1-Luc) or IL6 (NF-kB) luciferase reporter plasmid (IL-6-Luc) into P+ cells. The 46AP-1-Luc and IL-6-Luc reporters have been shown to be induced by 2 ± 3-fold in response to TPA or TNFa (Dong et al., 1995; Li et al., 1997) .
AP-1 dependent transactivation in P+ cells showed a threefold induction by TPA (Figure 3 ) in agreement with previous reports (Bernstein and Colburn, 1989; Dong et al., 1994 Dong et al., , 1995 . Transient co-transfection of pcDNA-pdcd4 and 46AP-1-Luc inhibited TPA-induced AP-1 dependent transactivation and basal AP-1 activity in a concentration dependent manner ( Figure  3 ). Both TPA-induced AP-1 transactivation and basal AP-1 transcriptional activity are approximately 50% inhibited by a 3 : 1 ratio of pcDNA-pdcd4 to reporter. Similar results were also observed when a collagenase promoter (773 to +67 bp) driven luciferase construct (Li et al., 1997) was used (data not shown). The region from 773 to +67 bp of the collagenase promoter contains one AP-1 binding site. Concentrations as high as 5 : 1 ratio of pcDNA-pdcd4 to reporter also show only 50% inhibition (data not shown). Previously, we found a 50% inhibition of AP-1 transactivation by tetracycline-regulated dominant negative c-jun TAM67 and observed 90% suppression of tumor phenotype in human keratinocytes (Li et al., 2000) . Therefore, this 50% inhibition of AP-1 transactivation by Pdcd4 may be sucient to suppress the neoplastic transformation. Figure 3 Concentration dependent inhibition of AP-1 transcriptional activity by Pdcd4. P+ cells were co-transfected with increasing amounts (0 ± 1.2 mg) of pcDNA-pdcd4 plasmid DNA and 0.4 mg of 46AP-1-luciferase report gene. Total DNA was maintained at 1.6 mg by adding pcDNA 3.1+ vector DNA. The luciferase activity from the cells with 0 mg of pcDNA-pdcd4 transfection and without TPA treatment is designated as 1. Results are expressed as the mean of three independent experiments+standard deviation. *Indicates signi®cant dierence compared with control (0 mg pdcd4 plus TPA) (P50.05). **Indicates signi®cant dierence compared with control (0 mg pdcd4 minus TPA) (P50.05)
In contrast, co-transfection of pcDNA-pdcd4 expression plasmid and IL-6-Luc produced a small but signi®cant increase of TNFa-induced NF-kB dependent transactivation (Figure 4 ) with an approximate 50% increase of NF-kB transactivtion by a 3 : 1 ratio of pcDNA-pdcd4 to reporter. In addition, although the fold induction was small in response to TPA treatment, the same 50% increase of NF-kB transactivation by a 3 : 1 ratio of pcDNA-pdcd4 to reporter was observed (data not shown). The basal NF-kB activity was unaected by co-transfection of pcDNA-pdcd4 plasmid. The stimulation of NF-kB activation by Pdcd4 indicates that inhibition of AP-1 transactivation by Pdcd4 does not occur as part of a general inhibition of transcription. If pdcd4 inhibits general transcription then reporter expression from any promoter should be inhibited regardless of whether the inducer is TPA, TNF, or something else. To further identify the speci®city with which pdcd4 targets transcription factors, we transiently transfected pcDNA-pdcd4 and serum response element (SRE)-luciferase reporter plasmid (SRE-Luc) into P+ cells. The results showed no signi®cant dierence in TPA-induced or basal SRE dependent transcriptional activity when pcDNA-pdcd4 was cotransfected with SRE-Luc ( Figure 5 ).
Expression of AP-1 proteins does not relieve inhibition of AP-1 by Pdcd4
To test whether Pdcd4 inhibition of AP-1 transactivation involves sequestering of Jun or Fos family components, we cotransfected fra-1, junD, or c-jun cDNA expression construct along with 46AP-1-Luc and with or without pcDNA-pdcd4. Fra-1 and JunD are two key components involved in AP-1 activation during neoplastic transformation in JB6 cells. Using mobility shift assays, Fra-1 and JunD have been demonstrated to participate in the activated form of AP-1-DNA complexes and found to bind to the AP-1 consensus sequence in response to TPA treatment in JB6 cells (Bernstein and Walker, 1999; MR Young and NH Colburn, unpublished data) . Therefore, here we tested only Fra-1, JunD and c-Jun enhanced AP-1 activity for possible antagonism by pdcd4. Any sequestering by Pdcd4 of endogenous AP-1 protein should be reversed by the ectopic introduction of the sequestered protein, thus relieving the inhibition of AP-1 by Pdcd4. As shown in Figure 6 , both basal and TPA-induced AP-1 transactivation were approximately 10 ± 40 fold enhanced when cells were transfected with fra-1, junD, or c-jun expression plasmid, as compared with those cells not transfected with pcDNA-pdcd4 or fra-1, c-jun, or junD cDNA expression plasmids. Cotransfection of pcDNA-pdcd4 (0.6 mg) with varied amounts of fra-1 expression plasmid (from 0 ± 0.6 mg) showed that expression of Fra-1 at up to a 1 : 1 ratio with Pdcd4 did not reverse the inhibition of AP-1 by Pdcd4 (Figure 6a ). The magnitude of AP-1 inhibition by 0.6 mg pdcd4 expression plasmid is about 50% in P+ cells without ectopic Fra-1 (compare 0 mg Fra-1, 0.6 mg pdcd4 to 0, 0); the magnitude of AP-1 inhibition by pdcd4 is about 95% when AP-1 activity is enhanced by ectopic Fra-1 expression (compare 0.6 mg Fra-1, 0.6 mg pdcd4 with 0.6 mg Fra-1, 0 mg pdcd4). Similarly, expression of either JunD or c-Jun also did not relieve Figure 4 Concentration dependent stimulation of TNF-induced NF-kB transcriptional activity. P+ cells were co-transfected with increasing amounts (0 ± 1.2 mg) of pcDNA-pdcd4 plasmid DNA and 0.4 mg of IL-6-luciferase report gene. The luciferase activity from the cells with 0 mg of pcDNA-pdcd4 transfection and without induction by TNF (like TPA, also a tumor promoter in JB6 cells) is designated as 1. Results are expressed as the mean of three independent experiments+standard deviation. *Indicates signi®cant dierence compared with control (0 mg pdcd4 plus TPA) (P50.05) Figure 5 No eect on SRE dependent transcriptional activity. P+ cells were co-transfected with increasing amounts (0 ± 0.8 mg) of pcDNA-pdcd4 plasmid DNA and 0.2 mg of SRE-luciferase reporter gene. Total DNA was maintained at 1.0 mg by adding pcDNA 3.1+ vector DNA. The luciferase activity from the cells with 0 mg of pcDNA-pdcd4 transfection and without TPA treatment is designated as 1. Results are expressed as the mean of three independent experiments+standard deviation the inhibition of basal or TPA-induced AP-1 activity seen in response to pdcd4 expression. (Figure 6b,c) . 1 : 1 expression of pdcd4 with each of the AP-1 proteins produced about 95% inhibition of the Jun or Fos enhanced level of AP-1 activation. These results indicate that Pdcd4 protein dominantly inhibits Fra-1, JunD and c-Jun enhanced AP-1 activity, thus arguing against a possible sequestration of AP-1 proteins or inhibition of Jun or Fos synthesis as a mechanism whereby Pdcd4 inhibits AP-1 transactivation.
Pdcd4 expression has no effect on ODC activity
To test whether Pdcd4 protein inhibits TPA induction of ODC activity, a required event for neoplastic transformation in JB6 cells, we analysed ODC activity in the pdcd4 pooled-clone P+ transfectants. Alteration of ODC enzyme activity by expression of pdcd4, if observed, could re¯ect pdcd4 eects on ODC mRNA or protein synthesis or stability or on enzyme activation since the basal activity and amount of ODC is very low without induction. The ODC activity was dramatically induced approximately 20 ± 50-fold after treatment with 15 ng/ml TPA for 12 h in both pdcd4 pooled-clone P+ transfectants (pdcd4-1 and pdcd4-4) and vector control pooled-clone P+ transfectants (vector-1 and vector-2) ( Table 1 ). The levels of basal and TPA-induced ODC activities in pdcd4 pooled-clone P+ transfectants were similar to those in vector control transfectants, indicating that expression of pdcd4 in P+ cells had no eect on ODC expression or activity. This observation is consistent with previous results that while P7 cells express elevated levels of Pdcd4 protein, there are no signi®cant ODC activity dierences between P7 and P+ cells (Jansen et al., 1999) .
Discussion
The present study demonstrates that elevating pdcd4 expression is sucient to inhibit the TPA-induced transformation in P+ cells. This transformation inhibitory activity may be attributable to inhibition of AP-1 activation but not to inhibition of certain other events required in tumor promoter induced neoplastic transformation, including NF-kB transactivation and ODC induction.
The use of a new peptide antibody that speci®cally recognizes Pdcd4 protein demonstrated that the level of Pdcd4 protein is approximately 8 ± 10-fold higher in P7 cells than in P+ cells, consistent with previous observations of preferential expression of the pdcd4 mRNA in P7 cells (Cmarik et al., 1999) . As shown by immunoblot (Figure 1) , the size of Pdcd4 protein is estimated at 64 kDa. This size is in agreement with observations of the human H731/Pdcd4 protein in HeLa cells ) but much Figure 6 Dominant inhibition of Fra-1-, JunD-, or c-Junenhanced AP-1 activity by Pdcd4. P+ cells were co-transfected with 0.2 mg of 46AP-1-Luc, 0 or 0.6 mg of pcDNA-pdcd4 and increasing amounts (0 ± 0.6 mg) of (a) fra-1, (b) junD, or (c) c-jun cDNA expression plasmid. Total DNA was maintained at 1.4 mg by adding pcDNA 3.1+ vector DNA. The luciferase activity from the cells with pcDNA-pdcd4 alone transfection and without TPA treatment is designated as 1. Results are expressed as the mean of three independent experiments+standard deviation. *Indicates signi®cant dierence compared with control (0 mg pdcd4 plus TPA) (P50.05). **Indicates signi®cant dierence compared with control (0 mg pdcd4 minus TPA) (P50.05) higher than the size predicted from the cDNA sequence (about 51 kDa). The higher molecular weight may arise from post-translational modi®cation since several consensus sites of phosphorylation, glycosylation, and myristoylation are identi®ed in Pdcd4 protein sequence. This peptide antibody will be valuable for further characterization of the Pdcd4 protein.
We previously showed that expression of antisense pdcd4 down-regulated endogenous Pdcd4 protein and resulted in conversion of transformation resistant P7 cells to the susceptible P+ phenotype (Cmarik et al., 1999) . Thus, down-regulation of pdcd4 was sucient for gain of transformation response. Here, we have shown that stable overexpression of pdcd4 cDNA in P+ cells resulted in increased Pdcd4 protein levels and acquisition of resistance to tumor promoter-induced transformation in soft agar (Figure 2) . Thus, elevating pdcd4 expression is sucient to inhibit neoplastic transformation. The levels of Pdcd4 protein in the three pdcd4 pooled-clone transfectants vary but all are higher than that in P+ cells while lower than that in P7 cells (Figure 2) . The magnitude of inhibition of TPA-induced transformation was not proportional to the expression of Pdcd4 protein since the pdcd4-3 and pdcd4-4 transfectants have similar levels of Pdcd4 protein but dierent magnitudes of transformation response (Figure 2) . This raises the possibility of a threshold of pdcd4 concentration above which inhibition occurs.
Studies with gene and small molecule inhibitors showed that AP-1 and NF-kB are coordinately regulated during tumor promoter-induced transformation in JB6 P+ cells (Li et al., 1997) as well as during mouse and human keratinocyte progression . Induction of tumor phenotype by TPA or TNFa occurs concomitantly with increased AP-1 and NF-kB activation (Li et al., 1997) . Inhibition of NF-kB activation by pyrrolidine dithiocarbamate, a speci®c inhibitor for NF-kB, resulted in inhibition of transformation and of AP-1 activation (Li et al., 1997) . In addition, inhibition of AP-1 by retinoid response was accompanied by NF-kB inhibition (Li et al., 1997) . E6/E7 immortalized human keratinocytes transfected with dominant negative c-jun TAM67 showed a reduction in the elevated AP-1 and NF-kB activities seen with progression and suppression of tumor phenotype (Li et al., 1998) . Activation of AP-1, NF-kB or both appears to target genes that are required for neoplastic transformation. The present observations (Figures 3 and 4) appear to be the ®rst to dissociate AP-1 activation from NF-kB activation.
Pdcd4 dominantly suppresses Fra-1, JunD or c-Jun enhanced AP-1 activates (Figure 6 ). These ®ndings suggest no direct protein ± protein interaction between Pdcd4 protein and Fra-1, JunD or c-Jun. They also suggest no indirect interaction of Pdcd4 with AP-1 proteins that might sequester them. This hypothesis is further supported by GST pull-down assays showing that GST-Pdcd4 does not pull down Fra-1, JunD or cJun (data not shown). Most likely, Pdcd4 regulates a mediator that controls AP-1 transactivation. Identi®ca-tion of the proteins directly interacting with Pdcd4 protein by yeast two-hybrid analysis will be important for elucidating the molecular mechanism by which Pdcd4 protein inhibits neoplastic transformation.
It is noteworthy that pdcd4 is up-regulated during drug-induced apoptosis in several model systems (Shibahara et al., 1995) . However, it is unknown whether pdcd4 expression is causally related to induction of apoptosis. Recent studies showed that Fas expression was up-regulated by NF-kB in Jurkat T cells during phorbol ester and ionomycin induced apoptosis (Chan et al., 1999) . Induction of NF-kB activity sensitizes some cells to apoptosis-inducing agents (Kasibhatla et al., 1999) . In addition, NF-kB can play a role in the regulation of cell cycle. For example, overexpression of chicken c-Rel in Hela cells causes cell cycle arrest (Bash et al., 1997) . In vivo studies using dominant negative IkBa transgenic mice demonstrated that functional loss of NF-kB resulted in hyperproliferation and functional gain of NF-kB, resulting in hypoproliferation in strati®ed epithelium (Seitz et al., 1998) . Therefore, one can consider the possibility that stimulation of NF-kB activation by pdcd4 expression inhibits neoplastic transformation through induction of apoptosis or cell cycle arrest.
In conclusion, these ®ndings establish that Pdcd4 protein functions as a transformation repressor, possibly through inhibiting AP-1 activation in combination with enhancing NF-kB activation. Pdcd4 protein may interact with a still unknown binding protein to inhibit AP-1 dependent transcriptional activity and to stimulate NFkB transcriptional activity.
Materials and methods
Plasmids and reagents pcDNA3.1+ vector was purchased from Invitrogen. Plasmid pcDNA-pdcd4 was generated by insertion of pdcd4 cDNA (Shibahara et al., 1995) into pcDNA 3.1+ vector between EcoRI and XbaI sites. 46AP-1 luciferase reporter plasmid (46AP-1-Luc) and NF-kB luciferase reporter plasmid (IL-6-Luc) were previously described (Dong et al., 1995; Li et al., 1997) . Serum response element (SRE)-luciferase reporter plasmid was purchased from Stratagene. Eagle's minimal essential medium (EMEM) was purchased from BioWhittaker; geneticin (G418), gentamicin, L-glutamine and fetal bovine serum were from Life Technologies; TPA was from Calbiochem; TNF-a was from BioWhittaker. FuGene 6 transfection reagent and complete mini protease inhibitor tablet were purchased from Roche Molecular Biochemicals. The luciferase Assay System was from Promega. The BCA protein assay kit was from Pierce.
Cell lines
The JB6 P+ (C141) and P7 (30.7b) cell lines were originally derived from BALB/c mouse primary epidermal cell cultures (Colburn et al., 1981) . Cells were routinely cultured in monolayer at 378C, 5% CO 2 using EMEM containing 4% fetal bovine serum, 2 mM L-glutamine and 25 mg/ml gentamicin.
Generation of pdcd4 antibody and Western blot
A 15 amino acid peptide corresponding to Pdcd4 protein from residues 455 ± 469 was synthesized. IgG antibodies against the 15 amino acid peptide were generated in rabbits by Spring Valley laboratories, Inc. (Sykesville, MD, USA). JB6 cells were washed twice with cold PBS and harvested by scraping in 200 ml of lysis buer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate and complete mini protease inhibitor tablet (1 tablet/10 ml lysis buer). Protein concentrations were determined by the BCA protein assay kit. Aliquots containing 10 mg of total protein were separated on 10% NuPage Bis-Tris polyacrylamide gel (Novex) and were transferred to nitrocellulose membranes. The immunoblot was performed as previously described (Cmarik et al., 1999) .
Reporter transfection and luciferase assay 1610 4 Cl 41 (P+) cells were seeded in 24-well plates in EMEM with 4% FBS. After 16 h, cells were transfected with 1.0 ± 1.6 mg DNA (as described in ®gure legends) using 2 ml of FuGene 6 transfection reagent and incubated at 378C, 5% CO 2 for 6 h. Cells were allowed to recover for 12 ± 18 h in 4% FBS EMEM medium before beginning tumor promoter treatment. For AP-1 dependent transcription assays, cells were treated with 15 ng/ml (25 mM) of TPA in 0.2% FBS EMEM medium for 18 h. For NF-kB and SRE transcription assays, cells were serum starved in EMEM with 0.2% FBS for 24 h and treated TNF-a (10 ng/ml) or TPA (15 ng/ml) for 3 h. Cells were then harvested for luciferase assay. Cells were lysed in 16passive buer for 20 min at room temperature and then frozen and thawed once. The bioluminescent signal was measured with a MLX Microtiter Plate Luminometer (Dynex Technologies). The transfection of replicate variability is +9% in Renilla luciferase unit values. All transfections was repeated at least twice using dierent preparation of DNAs.
For stable transfection, 5610 5 JB6 P+ cells were plated on a 100 mm plate. Cells were transfected with pcDNApdcd4 (15 mg) or pcDNA (15 mg) using 30 ml Lipofect-AMINE and 20 ml PLUS reagent for 5 h. After incubation in EMEM with 4% FBS for 48 h, transfected cells underwent selection for G418 (450 mg/ml) resistance for 12 ± 14 days in EMEM with 4% FBS.
Anchorage-independent transformation assay
The assay for Anchorage-independent transformation was carried out as previously described (Cmarik et al., 1999) . Brie¯y, 1610 4 cells were suspended in 0.33% BME agar containing 10% FBS and 10 ng/ml TPA (or solvent alone) layered over 0.5% BME agar containing 10% FBS and 10 ng/ml TPA (or solvent alone). The cultures were maintained at 378C, 5% CO 2 for 14 days, stained and scored by the methods previously described (Dong et al., 1994) .
ODC activity assay
Pooled clones pdcd4 transfectant cells (pdcd4-1, 4-3 and 4-4) and vector control cells were serum starved in EMEM supplemented with 0.2% FBS for 28 h. After treatment with TPA (15 ng/ml) or ethanol for 12 h, cells were harvested in 50 mM Tris-HCl (pH 7.5) buer containing 0.1 mM pyridoxal-5-phosphate, 0.1 mM EDTA and 0.1 mM DTT. ODC activity in the soluble extract was determined by measuring the release of 14 CO 2 from dl-[1-14 C]ornithine hydrochloride (Jansen et al., 1999) .
